News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
690,145 Results
Type
Article (39250)
Company Profile (250)
Press Release (650645)
Section
Business (203955)
Career Advice (2002)
Deals (35391)
Drug Delivery (89)
Drug Development (80894)
Employer Resources (168)
FDA (16114)
Job Trends (14816)
News (344749)
Policy (32460)
Tag
Academia (2530)
Alliances (49271)
Alzheimer's disease (1292)
Approvals (16078)
Artificial intelligence (169)
Bankruptcy (354)
Best Places to Work (11610)
Biotechnology (176)
Breast cancer (204)
Cancer (1546)
Cardiovascular disease (121)
Career advice (1667)
CAR-T (107)
Cell therapy (315)
Clinical research (64976)
Collaboration (583)
Compensation (312)
COVID-19 (2552)
C-suite (134)
Data (1487)
Diabetes (190)
Diagnostics (6202)
Earnings (85060)
Employer resources (146)
Events (110393)
Executive appointments (493)
FDA (16895)
Funding (525)
Gene therapy (216)
GLP-1 (626)
Government (4341)
Healthcare (18739)
Infectious disease (2649)
Inflammatory bowel disease (114)
Interviews (309)
IPO (16404)
Job creations (3625)
Job search strategy (1419)
Layoffs (425)
Legal (7871)
Lung cancer (230)
Manufacturing (216)
Medical device (13236)
Medtech (13241)
Mergers & acquisitions (19264)
Metabolic disorders (498)
Neuroscience (1657)
NextGen: Class of 2025 (6506)
Non-profit (4472)
Northern California (1881)
Obesity (284)
Opinion (187)
Patents (133)
People (56661)
Phase I (20229)
Phase II (28617)
Phase III (21316)
Pipeline (618)
Postmarket research (2562)
Preclinical (8555)
Radiopharmaceuticals (239)
Rare diseases (291)
Real estate (5894)
Regulatory (21800)
Research institute (2312)
Resumes & cover letters (349)
Southern California (1630)
Startups (3566)
United States (16792)
Vaccines (580)
Weight loss (195)
Date
Last 7 days (471)
Last 30 days (2114)
Last 365 days (34731)
2025 (2030)
2024 (35220)
2023 (40076)
2022 (51174)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (204)
Asia (37410)
Australia (6112)
California (4281)
Canada (1574)
China (366)
Colorado (194)
Connecticut (206)
Europe (80102)
Florida (615)
Georgia (150)
Illinois (422)
Indiana (245)
Maryland (685)
Massachusetts (3306)
Michigan (185)
Minnesota (316)
New Jersey (1201)
New York (1225)
North Carolina (790)
Northern California (1881)
Ohio (155)
Pennsylvania (1007)
South America (1093)
Southern California (1630)
Texas (628)
Utah (123)
Washington State (428)
690,145 Results for "lipocine inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
Lipocine Inc. today announced positive topline study results demonstrating bioequivalence of LPCN 1154 to IV brexanolone in an NDA enabling pivotal pharmacokinetic (PK) study. Lipocine is developing LPCN 1154, oral brexanolone, for the treatment of postpartum depression (PPD).
June 25, 2024
·
8 min read
Business
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.
May 9, 2024
·
10 min read
Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
Lipocine Inc. today announced that dosing of subjects has been completed in the pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154.
May 1, 2024
·
6 min read
Business
Lipocine to Present at 36th Annual Roth Conference
Lipocine Inc. today announced that Dr. Mahesh V. Patel , President and Chief Executive Officer, will participate in a fireside chat and meet with investors at the 36th Annual Roth Conference.
March 6, 2024
·
3 min read
Business
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
Lipocine Inc. today announced financial results for the year ended December 31, 2023 and provided a corporate update.
March 7, 2024
·
11 min read
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 results on LPCN 1148 in cirrhosis were featured in a late breaking oral presentation at the European Association for the Study of Liver (EASL) Congress on Saturday, June 8, in Milan, Italy.
June 10, 2024
·
7 min read
Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
Lipocine Inc. today announced that study enrollment is complete and the first cohort of subjects has been dosed in pivotal pharmacokinetic (PK) study designed to support a New Drug Application (NDA) for LPCN 1154. LPCN 1154.
March 25, 2024
·
6 min read
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
Lipocine Inc. today announced that results from a multi-dose clinical study have confirmed the LPCN 1154 48-hour dosing regimen for the upcoming NDA enabling pivotal pharmacokinetic (PK) study. LPCN 1154 is an oral neurosteroid being developed by Lipocine for the treatment of postpartum depression (PPD).
February 6, 2024
·
7 min read
BioMidwest
Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Lipocine Inc., a biopharmaceutical company, announced results from a Phase 2 clinical trial which includes LPCN 2401, an oral proprietary combination of anabolic androgen receptor agonist and α-tocopherol, an antioxidant.
April 11, 2024
·
11 min read
Drug Development
Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
Lipocine Inc., a biopharmaceutical company, announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver Congress, to take place June 5 to 8, 2024 in Milan, Italy.
May 8, 2024
·
4 min read
1 of 69,015
Next
